Immune checkpoint inhibitors, including anti–programmed cell death 1 (anti–PD-1) antibody and anti–programmed cell death ligand 1 (anti–PD-L1) antibody, have shown remarkable clinical benefits in certain cancer types, such as melanoma and lung cancer (2, 3), but have limited efficacy in OV (4). This evidence concerns the gene PDCD1 and lung carcinoma.